Objectives schwannomatosis is a dominantly inherited condition predisposing to schwannomas of mainly spinal and peripheral nerves with some diagnostic overlap with neurofibromatosis-2 (NF2), but the underlying epidemiology is poorly understood. We present the birth incidence and prevalence allowing for overlap with NF2. Methods schwannomatosis and NF2 cases were ascertained from the Manchester region of england (population=4.8 million) and from across the UK. point prevalence and birth incidence were calculated from regional birth statistics. Genetic analysis was also performed on NF2, LZTR1 and SMARCB1 on blood and tumour DNa samples when available. results Regional prevalence for schwannomatosis and NF2 were 1 in 126 315 and 50 500, respectively, with calculated birth incidences of 1 in 68 956 and 1 in 27 956. Mosaic NF2 causes a substantial overlap with schwannomatosis resulting in the misdiagnosis of at least 9% of schwannomatosis cases. LZTR1-associated schwannomatosis also causes a small number of cases that are misdiagnosed with NF2 (1%-2%), due to the occurrence of a unilateral vestibular schwannoma. patients with schwannomatosis had lower numbers of non-vestibular cranial schwannomas, but more peripheral and spinal nerve schwannomas with pain as a predominant presenting symptom. Life expectancy was significantly better in schwannomatosis (mean age at death 76.9) compared with NF2 (mean age at death 66.2; p=0.004). Conclusions Within the highly ascertained North-West england population, schwannomatosis has less than half the birth incidence and prevalence of NF2.
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INTrOduCTION
The autosomal-dominant tumour conditions schwannomatosis and neurofibromatosis-2 (NF2) both predispose individuals to development of schwannomas. Despite their phenotypical similarities, schwannomatosis has previously been shown to be a distinct entity from NF2, 1 2 mainly discriminated by the absence of vestibular schwannomas (VSs). In 2007, SMARCB1 was identified as a cause of schwannomatosis families and a minority of patients with sporadic schwannomatosis were shown to have pathogenic variants in the gene which lies 6 Mb centromeric to the NF2 gene on chromosome 22q. [3] [4] [5] [6] Following screening of SMARCB1 in our cohort, we reported that unilateral VS did appear to occur in a non-SMARCB1-related schwannomatosis family as well as other isolated cases. 7 A workshop acknowledged that the widely quoted schwannomatosis diagnostic criteria 8 should not have VS as a complete exclusion criterion for schwannomatosis (boxes 1 and 2). 9 No definitive diagnosis of VS has been reported in SMARCB1 related schwannomatosis. 10 However, with identification of the LZTR1 gene in 2014, 11 it became clear that VS did occur in the context of LZTR1-related schwannomatosis. 12 13 Indeed, we have also shown that isolated cases of VS aged under 25 years can harbour pathogenic variants in LZTR1.
14 Despite the fairly extensive epidemiological studies of NF2, [15] [16] [17] there has only been one report on schwannomatosis. This was based on pathology records from a small region in Finland. 18 This identified a fairly low calculated birth incidence for NF2 of 1 in 87 410 and annual incidence of schwannomatosis of 1 in 1 800 000. However, they found a similar prevalence of 10 and 11 cases, respectively. The similarity of the prevalences for the two conditions has led to the widespread quoting of a birth incidence figure of 1 in 40 000 for schwannomatosis 19 as this is similar to the original birth incidence of 1 in 33-40 000 quoted in the UK 15 and is reported on the Children's Tumour Foundation website (http://www. ctf. org/ understandingnf/ schwannomatosis) (accessed 9th March 2018). However, this figure has never been substantiated. The lack of a secure estimate for birth incidence and prevalence led us to perform an epidemiological analysis of schwannomatosis in the UK.
MeThOds
We have interrogated the UK national NF2 and schwannomatosis clinical database to identify patients meeting schwannomatosis and NF2 criteria boxes 1 and 2. All individuals meeting the study criteria underwent NF2 genetic testing of lymphocyte DNA (and tumour when available) using sequencing and Multiple Ligation dependant Probe Amplification (MLPA) of the NF2 gene. Subsequently, for patients with schwannomatosis or NF2 in whom no germline pathogenic variant was identified, sequencing and MLPA for LZTR1 and SMARCB1 were carried out. The Fisher's Exact test was used to calculate the significance of differences between proportions of people with various clinical features of NF2 and schwannomatosis. A two-tailed t-test was used to calculate the significance of differences between mean of ages at diagnosis and death between two groups. Significance was measured at p=0.05. Kaplan-Meier analysis was used to assess survival from birth.
For the most accurate estimate of birth incidence and prevalence, we used the region of North West England based around Manchester with a population of 4.8 million (excludes Merseyside), although national estimates were also calculated. The North West Regional family Genetic Register service (GR) covers the same region and pro-actively obtains details of families with each condition. The GR for NF2 was set up in 1990. Affected individuals and their families are referred from General Practitioners and specialists around the region. This is therefore likely the most highly ascertained UK population.
Cases of the two inherited conditions were confirmed in the Clinical Genetics department using existing diagnostic criteria (boxes 1 and 2). Dates of birth of all affected family members were recorded on the GR database and clinical databases for each condition. All deceased cases were confirmed if possible from medical records, cancer registry data or death certificates. Confirmation of the vast majority of living affected cases was through attendance at clinic appointments, although some gave consent for their records to be assessed. All regional patients received a full brain and spine MRI with 1-3 mm cuts through the internal auditory meatus. Repeat imaging was annual for brain in NF2 and 3-5 yearly for spine in both conditions.
Birth data for the region were obtained from The Office of Population Census and Surveys as well as the current population size. Birth dates for each decade starting in 1953 were mapped onto the regional population. All individuals with addresses outside the region were excluded from the analysis. Thus, 46 cases with NF2, and 12 with schwannomatosis, were not included. Birth incidence was taken as the highest incidence for a 10-year period as previously. 17 The highest rate was used for both conditions as prevalence for any birth cohort will be affected by either late diagnosis or early death. Using the maximal cohort provides the closest to total ascertainment which is likely to vary between conditions. Diagnostic prevalence was assessed on 01/03/2018 (prevalence day) for all those living with a diagnosis within the regional boundaries.
resulTs
A total of 1192 patients meeting NF2 criteria were identified in the UK with 932 alive on prevalence day giving a prevalence of 1 in 67 700 (table 1) . There were 399 identified as meeting schwannomatosis criteria giving a notional prevalence of 1 in 158 000 although vital status (whether alive) could not be confirmed in patients with schwannomatosis outside the region. Within the strict regional boundaries, there were 140 patients with NF2 identified with 95 confirmed alive on prevalence day giving a prevalence of 1 in 50 500. Equivalent figures for schwannomatosis were 44 with 37 alive giving a point prevalence of 1 in 126 135.
For birth incidence (table 2), the estimates for NF2 over a 31-year period (from 1953) were similar with the highest birth incidence estimated for 1974-1983 at 1 in 27 965. Although the highest estimate for schwannomatosis of 1 in 57 464 was obtained for the earliest birth cohort of 1953-1962, there were only 12 born before 1953 and only 5 in the 10 years before. Birth incidence estimates were much lower after 1973 reflecting the later age at diagnosis in schwannomatosis. The NF2 birth incidence figures are not affected by excluding the two cases of LZTR1-associated schwannomatosis as both were born before the study period. However, if the four cases of mosaic NF2 are removed from the schwannomatosis estimates, two patients are lost from the highest incidence period reducing the birth incidence estimate to 1 in 68 956.
Analysis for pathogenic variants in regional patients with a clinical diagnosis of NF2, in the geographic region analysed, identified most (79%) patients as having a causative change, although two (2%) without an NF2 variant had an LZTR1 pathogenic variant. None had a SMARCB1 pathogenic variant. Importantly, 35/139 (25%) had proven mosaicism, representing 37% of the 95 de novo cases. Only 30/95 (31.6%) of de novo cases had a full constitutional NF2 pathogenic variant with a similar number having no identified cause (largely as tumour was not available). Nineteen of the 35 mosaic cases were only identified after tumour analysis although 6/18 (33%) have subsequently been identified in blood after next generation sequencing with an allele frequency of 1.2%-3.3%. Overall, only 45/139 (32%) had inherited NF2 from their affected parent, although of these all 44 available for analysis had a confirmed NF2 pathogenic variant.
Of the 44 patients with phenotypical schwannomatosis in the geographic region analysed, 4 (9%) were found to have an identical NF2 pathogenic variant identified in two anatomically separate tumours confirming mosaic NF2. However, only seven patients had undergone analysis of more than one schwannoma. Eleven patients (25%) from four families had a pathogenic SMARCB1 variant and seven (16%) from six families had a pathogenic LZTR1 variant. Therefore, 50% of schwannomatosis cases in the geographic region analysed had no confirmed molecular diagnosis.
Of all 168 identified sporadic schwannomatosis cases that have undergone both SMARCB1 and LZTR1 testing, the proportion with an identified LZTR1 pathogenic variant (24.4%) was significantly higher than that with a SMARCB1 variant (13.7%; (p=0.01; table 3)). Although the reverse was true for families with multiple affected members, the trend was not statistically significant. Thirteen sporadic cases initially diagnosed with schwannomatosis were ultimately found to have mosaic NF2 (determined by identification of an identical pathogenic NF2 variant in two tumours). Three of these subsequently developed a unilateral VS. This represents 13/35 (37%) cases where two or more tumours were analysed.
Clinical features and tumour locations are shown in table 4 for cases in the geographic region. MRI scan information was not available for 10 NF2 cases who died before 1990 and one who is yet to undergo MRI screening with a family pathogenic variant. Six additional patients with NF2 had not undergone spinal imaging. Age at diagnosis and death was younger for NF2 than for schwannomatosis. Kaplan-Meier analysis (figure 1) showed significantly lower mean life expectancy of 66.2 for patients with NF2 than for schwannomatosis at 76.9 years (Breslow (Generalised Wilcoxon) p=0.004), pain without a visible or palpable mass was the most common presenting feature in schwannomatosis cases: 15/44 (35%), along with a peripheral nerve tumour. Ependymomas were not a feature of schwannomatosis and meningiomas were much less common (p<0.0001) than for NF2. Non-vestibular cranial nerve schwannomas occurred in schwannomatosis at about half the frequency of NF2, with trigeminal nerve lesions being the most common in both conditions. Unsurprisingly, VS were highly significantly more common in NF2 (p<0.0001). Peripheral nerve schwannomas were, nonetheless, more common in schwannomatosis at 81% versus 38.5% (p<0.0001), with spinal schwannomas being slightly (but not significantly) more common in schwannomatosis.
Neurogenetics Figure 1
Kaplan-Meier analysis showing survival from birth in regional patients with schwannomatosis and NF2. NF2, neurofibromatosis-2.
dIsCussION
The present study is the first large-scale study to assess the epidemiology of schwannomatosis. The prevalence in the UK at 1 in 155 000 and in the Manchester regional population of 1 in 126 135 is similar to the only previous estimate from Finland 18 which found 11 cases in a population of 1 557 200 (1 in 141 563). The authors studied incidence of schwannomatosis over a 10-year period from 1985 to 1995, but did not confirm vital status of the patients for a point prevalence. Although a birth incidence for NF2 was provided, no calculation was made for schwannomatosis. As such, our estimate from the highly ascertained region surrounding Manchester, where the lead author (DGE) has been identifying cases since 1990, of a birth incidence of 1 in 68 956 using the 10-year period 1953-1962 and excluding mosaic NF2 cases, is the only published estimate.
The present report confirms the previously described overlap between NF2 and schwannomatosis that is mainly due to VS occurring in LZTR1-associated schwannomatosis and mosaic NF2 mimicking schwannomatosis. 13 Although there is a single case report of an apparent unilateral VS in a SMARCB1 family, this potential association has not yet been validated. 20 While we are confident that no more than 1%-2% of NF2 is due to LZTR1, the proportion of sporadic schwannomatosis cases due to mosaic NF2 could be even higher than the 9% from our regional series. There was no diagnostic overlap with NF2 due to meningiomas in SMARCB1 related schwannomatosis. Of the 22 patients without a molecular diagnosis, only two had undergone testing of a second tumour (a third had an LZTR1 pathogenic variant). Nonetheless, overall only 13/35 (37%) of patients with schwannomatosis with two tumours analysed were due to mosaic NF2 although this proportion increases to 13/23 (57%), once cases with a germline LZTR1 or SMARCB1 pathogenic variant are excluded. If a 50% rate of mosaic NF2 holds true for the remainder of cases without a molecular diagnosis, then 14/44 (32%) regional cases could have mosaic NF2 rather than schwannomatosis. There is also the potential for underascertainment of schwannomatosis due to the non-specific features of presentation (pain) compared with NF2 (hearing loss, vertigo) and lack of recognition of the disorder by many general practitioners and plastic surgeons.
We have updated our work with regard to the proportion of schwannomatosis familial and sporadic cases having either a germline LZTR1 or SMARCB1 pathogenic variant. 12 There is still a likelihood of a further cause of familial schwannomatosis, since 14/45 (31%) of familial cases do not have a detectable underlying LZTR1 or SMARCB1 pathogenic variant. In comparison, a pathogenic NF2 variant was identified in 100% of familial regional NF2 cases. There are now six UK patients with unilateral VS (two regional) fulfilling NF2 criteria in this report as well as three with a sporadic VS and one with a sporadic facial schwannoma that have a pathogenic germline LZTR1 variant. 14 LZTR1 pathogenic variants are less common as a cause of familial schwannomatosis although they account for a greater proportion of sporadic cases. It is not known if this may be due to reduced penetrance or some other mechanism for LZTR1.
The current report also highlights clinical and tumour location differences between NF2 and schwannomatosis, which are similar to a report of 87 patients with schwannomatosis from the USA. 21 VS remain uncommon in schwannomatosis. Collectively, other cranial nerve schwannomas are more common, although still less common than in NF2. The later age at diagnosis in schwannomatosis is reflected in lower birth incidence estimates in the years after 1973, as many of these cases in the population are yet to present clinically. In contrast, the earlier deaths in NF2 mean that birth incidence estimates may be under-represented before 1974. We have compared survival in schwannomatosis with the known poorer life expectancy in NF2. 22 The near normal life expectancy in schwannomatosis was significantly better than NF2 for regional cases with high ascertainment. We believe this is the first recording of life expectancy estimates for schwannomatosis. Although some individuals who developed bilateral VS over 60 years of age may have developed these by chance, 23 this will not have affected estimates for the birth years 1974-1983. As such, the estimates presented here that now suggest a birth incidence above 1 in 30 000 and closer to the 1 in 25 000 estimated previously from VS diagnosis 16 are likely to be true. The schwannomatosis incidence is less secure, especially due to potential inclusion of mosaic NF2 cases. Nonetheless, it is likely that birth incidence is above 1 in 100 000 and, as many cases may not be diagnosed because of failure to suspect additional schwannomas in someone presenting with an apparently isolated tumour, the estimate of 1 in 60-70 000 may be realistic.
